Lasting Engraftment of Histoincompatible Bone Marrow

Vriesendorp, Huibert M.; Klapwijk, Wim M.; Kessel, Albert M.; Zürcher, C.; Bekkum, D.W. van

doi:10.1097/00007890-198105010-00009

Cited by 9 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sustained engraftment of DLA‐non‐identical grafts was seen only after preparative regimens with higher TBI doses than those used in the DLA‐identical HCT setting. TBI doses of 1500–1800 cGy were generally tolerated only when given in fractions 26,28,94,95 . When a TBI dose of 1800 cGy was given in three fractions of 600 cGy delivered at 2.1 cGy/min at 48‐h intervals, the immunosuppression achieved was sufficient to allow sustained engraftment of unrelated DLA‐incompatible marrow grafts 95 .…”

Section: Conditioning Regimensmentioning

confidence: 99%

Five decades of progress in haematopoietic cell transplantation based on the preclinical canine model

Lupu

Storb

2007

Vet Comparative Oncology

View full text Add to dashboard Cite

The preclinical canine model has proved valuable for the development of principles and techniques of haematopoietic cell transplantation (HCT) applicable to human patients. Studies in random-bred dogs concerning the impact of histocompatibility barriers on engraftment and graft-versus-host disease, the kinetics of immunological reconstitution, the effi cacy of various pretransplant conditioning regimens, post-transplantation immunosuppression protocols, treatment of malignant diseases, and graft-versus-tumour effects have advanced HCT from an investigational therapy with uncertain clinical benefi t half a century ago to an important treatment choice for thousands of patients treated annually in transplantation centres worldwide. More recent preclinical canine studies have resulted in the clinical translation of non-myeloablative, minimally invasive transplantation protocols that have extended allogeneic HCT to include older human patients with malignant and non-malignant, acquired or inherited haematological disorders, and those with comorbid conditions. Here, we review the contributions of the canine model to modern HCT and describe the usefulness of HCT for the treatment of canine haematological disorders.

show abstract

Section: Conditioning Regimensmentioning

confidence: 99%